Remdesivir, Drugs Monitor, Page 2

(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19

October 17, 2020

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 The interim results from Solidarity trials (ISRCTN83971151 , NCT04315948 ) are presented. In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon… Continue reading "(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19"

(22 Aug 2020) Remdesivir- No statistical significant difference compared to SOC

August 26, 2020

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial https://doi.org/10.1001/jama.2020.16349 Among 596 patients who were randomized, 584 began the study and received remdesivir or continued standard care (median… Continue reading "(22 Aug 2020) Remdesivir- No statistical significant difference compared to SOC"

(28 July 2020) Remdesivir- associated with significantly greater recovery and 62% reduced odds of death

July 28, 2020

Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care https://doi.org/10.1093/cid/ciaa1041 NCT04292899/GS-US-540-5773 is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort). Inclusion criteria were similar between studies: patients had confirmed SARS-CoV-2 infection, were hospitalized,… Continue reading "(28 July 2020) Remdesivir- associated with significantly greater recovery and 62% reduced odds of death"

(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19

June 30, 2020

Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials https://doi.org/10.1101/2020.06.22.20136531 This study is registered at INPLASY (INPLASY202060046). PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for… Continue reading "(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19"

(28 June 2020) Remdesivir- exhibits favorable safety and PK profiles

June 29, 2020

Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12840 This report describes two phase 1 studies that evaluated the safety and pharmacokinetics (PK) of single escalating and multiple intravenous (IV) doses of RDV… Continue reading "(28 June 2020) Remdesivir- exhibits favorable safety and PK profiles"

(10 June 2020) Remdesivir- virus titers reduced in 12 hrs after the first treatment administration in rhesus macaque model

June 11, 2020

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 https://doi.org/10.1038/s41586-020-2423-5 The efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection was investigated. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of… Continue reading "(10 June 2020) Remdesivir- virus titers reduced in 12 hrs after the first treatment administration in rhesus macaque model"

(27 May 2020) Remdesivir- no significant difference between a 5-day and a 10-day course

May 28, 2020

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2015301?query=featured_home In a randomized, open-label, phase 3 trial (NCT04292899)involving hospitalized patients with confirmed SARS-CoV-2 infection. In total, 397 patients underwent randomization and began treatment (200 patients for 5 days… Continue reading "(27 May 2020) Remdesivir- no significant difference between a 5-day and a 10-day course"

(22 May 2020) Remdesivir- shortened time to recovery

May 23, 2020

Remdesivir for the Treatment of Covid-19 — Preliminary Report https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time… Continue reading "(22 May 2020) Remdesivir- shortened time to recovery"

(18 May 2020) Remdesivir- preliminary evidence of in-vivo virological effect

May 19, 2020

Early experience with remdesivir in SARS-CoV-2 pneumonia https://link.springer.com/article/10.1007/s15010-020-01448-x This case report describes an early experience with remdesivir in four critically ill COVID-19 patients admitted to the Monaldi Hospital, Naples, Italy. Patients received a 200 mg loading dose, followed by 100… Continue reading "(18 May 2020) Remdesivir- preliminary evidence of in-vivo virological effect"

(08 May 2020) Remdesivir- Faster recovery rates

May 11, 2020

Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study https://doi.org/10.1101/2020.05.02.20088559 Findings from simulated two arm study suggests that Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and… Continue reading "(08 May 2020) Remdesivir- Faster recovery rates"

Tag: Remdesivir